Sigyn Therapeutics, Inc.
SIGY
$4.10
-$0.0099-0.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.86M | 1.69M | 1.68M | 1.66M | 1.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.76M | 2.59M | 2.56M | 2.46M | 2.21M |
| Operating Income | -2.76M | -2.59M | -2.56M | -2.46M | -2.21M |
| Income Before Tax | -3.99M | -3.70M | -3.56M | -4.15M | -3.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.99 | -3.70 | -3.56 | -4.15 | -3.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.99M | -3.70M | -3.56M | -4.15M | -3.83M |
| EBIT | -2.76M | -2.59M | -2.56M | -2.46M | -2.21M |
| EBITDA | -2.75M | -2.58M | -2.55M | -2.44M | -2.20M |
| EPS Basic | -3.20 | -3.07 | -3.04 | -3.82 | -3.79 |
| Normalized Basic EPS | -2.18 | -2.10 | -2.20 | -2.70 | -2.50 |
| EPS Diluted | -3.23 | -3.11 | -3.08 | -3.85 | -3.80 |
| Normalized Diluted EPS | -2.18 | -2.10 | -2.20 | -2.70 | -2.50 |
| Average Basic Shares Outstanding | 4.99M | 4.82M | 4.67M | 4.40M | 4.09M |
| Average Diluted Shares Outstanding | 4.99M | 4.82M | 4.67M | 4.40M | 4.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
